Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeFUNDINGSheaumann Laser Receives $2.3M Massachusetts Manufacturing Innovation Initiative Award

Sheaumann Laser Receives $2.3M Massachusetts Manufacturing Innovation Initiative Award

The company expand laser manufacturing capability in Marlborough facility.


Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets –

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts –

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.
Sheaumann Laser was recently awarded $2.345 million from the Massachusetts Manufacturing Innovation Initiative (M2I2). Sheaumann Laser specializes in the design and manufacture of semiconductor lasers and modules for industrial, defense, medical, and printing applications. The grant will play a key role in growing Sheaumann’s laser wavelength capability (currently from 780 to 1080 nm) to lasers with wavelengths from 1120 nm to 1875 nm. This growth will nearly double its production capability and add new Marlborough-based jobs.
“The M2I2 program invests in projects that reflect the collaborative spirit of our state and highlight Massachusetts’ nation leading innovation economy,” said Governor Charlie Baker. “These awards support strong business to business partnerships that bring together innovators from across the state, and we are pleased to continue to support their continued growth and development in this sector.” The grant to Sheaumann was uncommonly large for the M2I2 program, recognizing the company’s position as a strong anchor of the Massachusetts economy.
Gary Sousa, Sheaumann’s President, stated at the award ceremony, “While other semiconductor laser foundries have moved overseas to reduce production costs and maintain a competitive advantage in the market, this solution has never been an option for Sheaumann Laser, because we take pride in providing our customers with high-quality laser products that are grown, processed, and packaged in the United States.”
Sheaumann anticipates moving forward quickly with their plans to expand in response to the explosion in growth within the laser diode industry.  “As more industries find new ways to incorporate the capabilities and advantages of laser diodes into their systems, we are seeing increased demand in a variety of new market sectors,” Sousa said.  “We look forward to applying the grant from M2I2 to help us meet those needs.”


AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy